On March 17, 2022, the Board of Directors (the Board) of Emergent BioSolutions Inc. (the Company) appointed Keith Katkin as a Class I director of the Company, effective as of April 1, 2022 (the Effective Date), with an initial term expiring at the 2022 annual meeting of stockholders. He was also appointed as a member of both the Nominating and Corporate Governance Committee and Strategic Operations Committee of the Board, as of the Effective Date.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.56 USD | -9.00% | +17.80% | +131.67% |
May. 02 | Sector Update: Health Care Stocks Softer Late Afternoon | MT |
May. 02 | Sector Update: Health Care | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+131.67% | 291M | |
+42.83% | 750B | |
+34.11% | 606B | |
-5.70% | 356B | |
+18.06% | 326B | |
+4.63% | 286B | |
+17.91% | 246B | |
+10.77% | 213B | |
-3.03% | 213B | |
+2.43% | 167B |
- Stock Market
- Equities
- EBS Stock
- News Emergent BioSolutions Inc.
- Emergent BioSolutions Inc. Appoints Keith Katkin as a Class I Director, Member of Both the Nominating and Corporate Governance Committee and Strategic Operations Committee of the Board